VAV1: An Emerging Target in Targeted Protein Degradation Technology
In recent years, targeted protein degradation (TPD) technology has rapidly emerged as an important paradigm in drug development. VAV1, as an emerging target, has garnered significant attention due to its potential therapeutic value in autoimmune and chronic inflammatory diseases.
- Recent Advances
- Product Information
VAV1
VAV1: An Emerging Target in Targeted Protein Degradation Technology
In recent years, targeted protein degradation (TPD) technology has rapidly emerged as an important paradigm in drug development. VAV1, as an emerging target, has garnered significant attention due to its potential therapeutic value in autoimmune and chronic inflammatory diseases.
VAV1: A Key Factor in Immunomodulation
VAV1 is a multifunctional signal transduction protein widely present in immune cells such as T cells and B cells. It is involved in cytoskeletal reorganization, cytokine secretion, immunologic synapse formation, and cell migration. Aberrant activation of VAV1 is closely associated with various autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease. Therefore, precise regulation of VAV1 function holds promise for breakthroughs in treating these conditions.
Youai VAV1 Protein: Bridging Research and Clinical Practice
Youai is committed to providing researchers with high-quality VAV1 protein to support in-depth research into its role in immunomodulation. Youai's VAV1 protein undergoes rigorous purification, ensuring high activity and strong specificity. It is suitable for various experimental scenarios and can meet your diverse needs.
Clinical Prospects: From Laboratory to Patients
The development of VAV1 molecular glues offers new avenues for treating autoimmune and chronic inflammatory diseases. MRT-6160, a VAV1 molecular glue developed by Monte Rosa Therapeutics, has demonstrated significant therapeutic effects in preclinical models and is currently undergoing Phase I clinical trials. This not only underscores the potential of VAV1 as a therapeutic target but also lays a solid foundation for future drug development.
Choose Youai, Choose the Future
On the journey of immunotherapy, Youai walks hand in hand with you. Our VAV1 protein is a reliable partner for exploring the mysteries of immunology, assisting you in advancing from the laboratory to the clinic and bringing new hope to patients. Choose Youai, choose the future!
Available Products:
|
Catalog Number |
Product |
|
UA080427 |
VAV1 Protein, Human |
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 